Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conbercept
- Development stage
- Phase 4
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
Conbercept is a recombinant fusion protein designed as a soluble decoy receptor that inhibits vascular endothelial growth factor (VEGF) signaling. It consists of the second Ig domain of VEGFR-1 and the third and fourth Ig domains of VEGFR-2 fused to the Fc portion of human IgG1. Conbercept binds with high affinity to multiple isoforms of VEGF-A, as well as VEGF-B and placental growth factor (PlGF), thereby blocking their interaction with endogenous receptors on the surface of endothelial cells. This inhibition suppresses abnormal blood vessel growth and leakage in retinal diseases. Developed by Chengdu Kanghong Pharmaceutical Group, conbercept is primarily indicated for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and choroidal neovascularization secondary to pathologic myopia[1][4][5].
- Brand names
- Lumitin
- Other names
- recombinant human VEGF receptor-Fc fusion protein康柏西普
02
Targets
VEGFC (VEGF-C)VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on conbercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conbercept.